Results are intended to support more informed conversations with healthcare providers about individual response probability
55 The SURMOUNT Program includes four global phase 3, randomized, placebo-controlled clinical trials with tirzepatide administered subcutaneously once weekly in conjunction with lifestyle intervention.47, 48, 49 There was a substantial degree of weight reduction with 10 mg and 15 mg doses of 18.420.9% in persons with obesity or preobesity (without diabetes), with improvements in cardiometabolic risk factors (Table 2).47, 48, 49 Lower bodyweight reductions of 12.8% and 14.7% with 10 mg and 15 mg doses of tirzepatide, respectively, were observed in persons with preobesity or obesity and T2DM
Alternative dilution: Add 2 ml of BAC water for more concentrated working solution if smaller draw volumes are required
Patients should discuss the trade-offs with a licensed provider
Research indicates that these medications can increase "natriuresis," which is the process of the kidneys excreting sodium through urine
Erastin/sorafenib induces cisplatin-resistant non-small cell lung cancer cell ferroptosis through inhibition of the Nrf2/xCT pathway
